Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis
Mohammad S. Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, Alissa Visram, Ghulam Rehman Mohyuddin, Christopher P. Venner, Irwindeep Sandhu, Arleigh McCurdy, Thierry Facon, Maria-Victoria Mateos, Hira Mian · 2024
Read Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis by Mohammad S. Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, Alissa Visram, Ghulam Rehman Mohyuddin, Christopher P. Venner, Irwindeep Sandhu, Arleigh McCurdy, Thierry Facon, Maria-Victoria Mateos, Hira Mian (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11629212.txt.
Description
Mohammad Ebraheem and co-authors pool the trials of four-drug regimens for people newly diagnosed with multiple myeloma. The quadruplets add an anti-CD38 antibody to a backbone of a proteasome inhibitor and an immunomodulatory drug. The team searched the big databases, trial registries, and meeting libraries to January 2024 for randomized trials that compared the four-drug mix with the same backbone alone.
Seven trials with 3,716 patients qualified. Against triplets, quadruplets raised the overall response rate a notch. They cut the risk of progression or death near in half. Far more patients reached minimal residual disease negativity, at both the one-in-a-hundred-thousand and one-in-a-million test levels. Overall survival improved as well. For a disease where depth of response foretells length of control, the review gives the four-drug opening a firm evidence base.
Catalog record
| CREATOR | Mohammad S. Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, Alissa Visram, Ghulam Rehman Mohyuddin, Christopher P. Venner, Irwindeep Sandhu, Arleigh McCurdy, Thierry Facon, Maria-Victoria Mateos, Hira Mian |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |